Clinical trials: Heart Diseases
Congenital Heart Disease
ABL90 FP MC Neonatal Arterial, Venous, Capillary Blood
The goal of this clinical trial is to validate performance claims for method comparison for ABL90 FLEX PLUS in heparinized neonatal arterial, venous, and capillary whole blood for ctBil and FHbF in a Point of Care (POC) setting.
- Trial name
- NCT06078943
- Testing
- method comparison
- Where
- United States
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Radiometer Medical ApS
Myocardial Infarction
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
The general aim of this study was to assess the feasibility of treating acute myocardial infarction (AMI) by physician-directed pre-hospital thrombosis, using accelerated alteplase (Actilyse®) and a diagnostic technique involving…
- Trial name
- PHARAOH (NCT02235389)
- Testing
- Alteplase (Actilyse), Standard therapy
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System
The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT01570517
- Testing
- IASD System
- Where
- 3 sites in Australia, Czechia and 1 more
- Volunteers
- 11 people
- Sponsor
- Corvia Medical
Atrial Fibrillation, Paroxysmal, Atrial Fibrillation, Persistent
MultiPulse Therapy (MPT) for AF
Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation waveform sequence in terminating paroxysmal and persistent atrial fibrillation.
- Conditions
- Atrial Fibrillation, Paroxysmal, Atrial Fibrillation, Persistent, Atrial Fibrillation
- Trial name
- NCT04206917
- Testing
- Multi Pulse Therapy
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Cardialen, Inc.
Coronary Artery Disease, Coronary Restenosis
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)
The primary objective of this study is determine the safety and performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter for the treatment of…
- Conditions
- Coronary Artery Disease, Coronary Restenosis, Coronary Atherosclerosis, Coronary Arteriosclerosis
- Trial name
- AGENT-ISR (NCT02151812)
- Testing
- Agent Paclitaxel-coated balloon, SeQuent® Please Paclitaxel-coated Balloon
- Where
- 12 sites in France, Germany
- Volunteers
- 123 people
- Sponsor
- Hemoteq AG
Heart Failure
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in…
- Trial name
- NCT07376265
- Where
- United States
- Volunteers
- 1,249 people
- Sponsor
- Novartis Pharmaceuticals
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician…
- Trial name
- SPARC-HCM (NCT07557498)
- Testing
- Mavacamten
- Where
- United Kingdom
- Volunteers
- 362 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease, General Anesthetic Drug Allergy
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies.
- Conditions
- Coronary Artery Disease, General Anesthetic Drug Allergy, Coronary Artery Bypass Graft Surgery
- Trial name
- NCT01294163
- Testing
- Xenon, Sevoflurane, Propofol
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 509 people
- Sponsor
- Air Liquide Santé International
Turner Syndrome
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
This is a multicenter, randomized, open-label, positive-controlled phase III confirmatory clinical study. A total of 84 children with short stature due to Turner Syndrome (TS) are planned to be enrolled.
- Trial name
- NCT07614152
- Testing
- Inpegsomatropin-Injection, Givopegsomatropin Solution Injection
- Where
- 51 sites in China
- Volunteers
- 84 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Heart Failure With Preserved Ejection Fraction
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF.
- Trial name
- CAPACITY-HFpEF (NCT03254485)
- Testing
- IW-1973
- Where
- 62 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Akebia Therapeutics
Atrial Fibrillation
Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation
Primary Objective: To assess the efficacy of dronedarone versus placebo for the control of ventricular rate in patients with permanent Atrial Fibrillation (AF).
- Trial name
- NCT01213368
- Testing
- DRONEDARONE (SR33589)
- Where
- 25 sites in Japan
- Volunteers
- 181 people
- Sponsor
- Sanofi
Tricuspid Regurgitation
TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System
This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation.
- Trial name
- NCT07334691
- Testing
- Cardiovalve TR valve replacement System
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Cardiovalve Ltd.
Dyslipidemia, Atherosclerosis
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
- Conditions
- Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
- Trial name
- NCT00768274
- Testing
- RVX000222
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Resverlogix Corp
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Atrial Fibrillation
Exploratory Safety and Effectiveness Evaluation of Pulsed Field Ablation (PFA) by Balloon Catheter With TRUPULSE Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF)
The purpose of this study is to explore preliminary safety and acute effectiveness of pulsed field ablation by the ablation system (pulsed field ablation balloon catheter and TRUPULSE generator) when used for isolation of the…
- Trial name
- ZephIRE (NCT06495216)
- Testing
- Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator
- Sponsor
- Biosense Webster, Inc.
Coronary Artery Disease, Coronary Artery Stenosis
ABSORB III Randomized Controlled Trial (RCT)
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB-III (NCT01751906)
- Testing
- Absorb BVS, XIENCE
- Where
- 192 sites in United States, Australia
- Volunteers
- 2,008 people
- Sponsor
- Abbott Medical Devices
Cardiac Arrest, Heart Arrest
ICD Shock Detection by a Wearable
Trial to assess the ability of a wearable to detect defibrillation from an implantable ICD
- Conditions
- Cardiac Arrest, Heart Arrest, Cardiopulmonary Arrest
- Trial name
- LOISICD (NCT04565652)
- Testing
- Device Wearers
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Lois Medical LTD
Atrioventricular Block, Ventricular Dysfunction
Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
The primary purpose of the study is to evaluate if patients with a standard indication for permanent ventricular pacing, left ventricular ejection fraction without limit, or any QRS duration will profit from the prevention of…
- Trial name
- NCT00187278
- Testing
- Biventricular Pacing, RV Pacing
- Where
- Germany
- Volunteers
- 1,833 people
- Sponsor
- Abbott Medical Devices
Saphenous Vein Graft Disease, Myocardial Ischemia
The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts
This is a multicenter, prospective study designed to demonstrate the performance and safety of the FiberNet Embolic Protection System when used as an adjunctive device during saphenous vein graft (SVG) intervention.
- Conditions
- Saphenous Vein Graft Disease, Myocardial Ischemia, Embolism
- Trial name
- RETRIEVE (NCT00453518)
- Testing
- FiberNet EPS used during SVG intervention.
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lumen Biomedical
Heart Failure
Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients
Patients with heart failure are reported to have lower levels of hydrogen sulfide in their blood, even though sulfur is available naturally in the diet.
- Trial name
- NCT01989208
- Testing
- SG1002
- Where
- 2 sites in Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sulfagenix Australia Pty Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.